ABT vs PFE
ABT: Abbott is a diversified healthcare conglomerate manufacturing diagnostics, nutritional products, pharmaceuticals, and medical devices with recent expansion into cancer diagnostics through Exact Sciences acquisition. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | ABT | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $94.40 | $24.25 | |
| Market cap as of 2026-07-10 | $164.5B | $138.1B | |
| P/E as of 2026-07-10 | 26.21 | 18.44 | PFE lower |
| PEG as of 2026-07-10 | 2.66 | -3.38 | PFE lower |
| Net margin as of 2026-07-10 | +13.9% | +11.8% | ABT higher |
| Gross margin as of 2026-07-10 | +56.5% | +74.8% | PFE higher |
| Operating margin as of 2026-07-10 | +17.1% | +15.4% | ABT higher |
| ROE as of 2026-07-10 | +12.2% | +8.4% | ABT higher |
| ROA as of 2026-07-10 | +6.9% | +3.6% | ABT higher |
| Debt / equity as of 2026-07-10 | 0.65 | 0.72 | ABT lower |
| Revenue growth (YoY) as of 2026-07-10 | +6.6% | +1.4% | ABT higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -14.8% | ABT higher |
| Dividend yield as of 2026-07-10 | +2.6% | +7.1% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | PFE higher |
| Beta as of 2026-07-10 | 0.59 | 0.29 | |
| 1-year return as of 2026-07-09 close | -29.1% | -5.1% | PFE higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.